论文标题
使用簇理论计算抗体溶液的实验结构因子
Using cluster theory to calculate the experimental structure factors of antibody solutions
论文作者
论文摘要
在未来几年中,单克隆抗体溶液将成为一种主要的治疗工具,能够通过巧妙地设计其抗原结合位点来靶向各种疾病。但是,由于粘度的增加,通常在高浓度下发生的粘度增加,适合患者自我给药的稳定溶液通常会带来挑战。在这里,我们通过表征簇的表征在显微镜分子细节和抗体溶液的产生特性之间建立了联系,在存在自缔解抗体的情况下会产生。特别是,我们发现可以根据此类簇的存在来解释实验性的小角度X射线散射数据。后者由理论计算确定,并由粗粒度最小模型的计算机模拟支持,其中将抗体视为Y形胶体分子,并且有吸引力的域被设计为斑块。使用理论预测的簇尺寸分布,我们能够描述在广泛的浓度和盐条件下的实验结构因子。因此,我们提供了一个显着的证据,证明了一个公认的事实,即粘度的浓度依赖性增加是由簇的存在起源的。我们的发现为单克隆抗体的自组装带来了新的见解,可以利用这些抗体来指导稳定有效的抗体溶液的制定。
Monoclonal antibody solutions are set to become a major therapeutic tool in the years to come, capable of targeting various diseases by clever designing their antigen binding site. However, the formulation of stable solutions suitable for patient self-administration typically presents challenges, as a result of the increase in viscosity that often occurs at high concentrations. Here, we establish a link between the microscopic molecular details and the resulting properties of an antibody solution through the characterization of clusters, which arise in the presence of self-associating antibodies. In particular, we find that experimental small-angle X-ray scattering data can be interpreted by means of analytical models previously exploited for the study of polymeric and colloidal objects, based on the presence of such clusters. The latter are determined by theoretical calculations and supported by computer simulations of a coarse-grained minimal model, in which antibodies are treated as Y-shaped colloidal molecules and attractive domains are designed as patches. Using the theoretically-predicted cluster size distributions, we are able to describe the experimental structure factors over a wide range of concentration and salt conditions. We thus provide microscopic evidence for the well-established fact that the concentration-dependent increase in viscosity is originated by the presence of clusters. Our findings bring new insights on the self-assembly of monoclonal antibodies, which can be exploited for guiding the formulation of stable and effective antibody solutions.